دورية أكاديمية
Pediatric and adolescent HIV viral load coverage and suppression rates in the context of the COVID-19 pandemic in 12 PEPFAR-supported sub-Saharan African countries in 2019 and 2020.
| العنوان: | Pediatric and adolescent HIV viral load coverage and suppression rates in the context of the COVID-19 pandemic in 12 PEPFAR-supported sub-Saharan African countries in 2019 and 2020. |
|---|---|
| المؤلفون: | Carpenter D; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia., Hast M; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia., Buono N; United States Agency for International Development, Washington, District of Columbia, United States of America., Hrapcak S; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia., Sato K; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia., Mrina R; Walter Reed Army Institute of Research, United States Military HIV Research Program, Silver Spring, Maryland, United States of America.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America., Cox MH; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia., Agaba PA; Walter Reed Army Institute of Research, United States Military HIV Research Program, Silver Spring, Maryland, United States of America.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America., Vrazo AC; United States Agency for International Development, Washington, District of Columbia, United States of America., Wolf H; US Department of State, Office of the United States Global AIDS Coordinator, Washington, District of Columbia, United States of America., Rivadeneira ED; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia., Shang JD; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Yaounde, Cameroon., Mayer MM; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Yaounde, Cameroon., Prao AH; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Abidjan, Côte d'Ivoire., Longuma HO; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Kinshasa, Democratic Republic of Congo., Kabwe C; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Kinshasa, Democratic Republic of Congo., Lwana PN; Ministry of Health, National AIDS Control Committee, Kinshasa, Democratic Republic of Congo., Tilahun T; United States Agency for International Development, Addis Ababa, Ethiopia., Ts'oeu M; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Maseru, Lesotho., Mutisya I; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Nairobi, Kenya., Omoto LN; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Nairobi, Kenya., Cowan JG; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Maputo, Mozambique., Deus MIJT; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Maputo, Mozambique., Fagbamigbe OJ; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Nigeria., Ene U; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Nigeria., Ikpeazu A; Federal Ministry of Health, Abuja, Nigeria., Ndlovu MB; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Pretoria, South Africa., Matiko E; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Dar es Salaam, Tanzania., Schaad N; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Dar es Salaam, Tanzania., Bisimba J; United States Agency for International Development, Dar es Salaam, Tanzania., Lema E; United States Agency for International Development, Dar es Salaam, Tanzania., Musokotwane K; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Lusaka, Zambia., Maphosa T; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Harare, Zimbabwe., Buthelezi B; United States Agency for International Development, Pretoria, South Africa., Olarinoye A; HJF Medical Research International, Abuja, Nigeria., Lawal I; US Army Medical Research Directorate-Africa/ Walter Reed Army Institute of Research, Abuja, Nigeria., Mukungunugwa S; United States Agency for International Development, Harare, Zimbabwe., Mwambona JT; Walter Reed Army Institute of Research (WRAIR), Dar es Salaam, Tanzania., Wondimu T; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Addis Ababa, Ethiopia., Kathure IA; United States Agency for International Development, Nairobi, Kenya., Igboelina OD; United States Agency for International Development, Abuja, Nigeria., Nzima VN; United States Agency for International Development, Yaounde, Cameroon., Bissai RG; United States Agency for International Development, Yaounde, Cameroon., Lenka M; United States Agency for International Development, Maseru, Lesotho., Shasha W; United States Agency for International Development, Abidjan, Côte d'Ivoire., Olivier NK; United States Agency for International Development, Abidjan, Côte d'Ivoire., Matsinhe M; United States Agency for International Development, Maputo, Mozambique., Wate A; United States Agency for International Development, Maputo, Mozambique., Godfrey L; United States Agency for International Development, Lusaka, Zambia., Alexander H; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia., Alemnji G; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia., Lecher S; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia. |
| المصدر: | PLOS global public health [PLOS Glob Public Health] 2024 Aug 01; Vol. 4 (8), pp. e0003513. Date of Electronic Publication: 2024 Aug 01 (Print Publication: 2024). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 9918283779606676 Publication Model: eCollection Cited Medium: Internet ISSN: 2767-3375 (Electronic) Linking ISSN: 27673375 NLM ISO Abbreviation: PLOS Glob Public Health Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: San Francisco, California : Public Library of Science, [2021]- |
| مستخلص: | The early period of the COVID-19 pandemic limited access to HIV services for children and adolescents living with HIV (C/ALHIV). To determine progress in providing care and treatment services, we describe viral load coverage (VLC) and suppression (VLS) (<1000 copies/ mL) rates during the COVID-19 pandemic in 12 United States President's Emergency Plan for AIDS Relief (PEPFAR)-supported countries. Data for children (0-9 years) and adolescents (10-19 years) on VLC and VLS were analyzed for 12 sub-Saharan African (SSA) countries between 2019 (pre-COVID-19) and 2020 (during COVID-19). We report the number of viral load (VL) tests, and percent change in VLC and VLS for patients on ART. For 12 countries, 181,192 children had a VL test during the pre-COVID-19 period compared with 177,683 December 2020 during COVID-19. VLC decreased from 68.8% to 68.3% overall. However, 9 countries experienced an increase ranging from a 0.7%-point increase for Tanzania and Zimbabwe to a 15.3%-point increase for Nigeria. VLS increased for all countries from 71.2% to 77.7%. For adolescents the number with a VL test increased from 377,342 to 402,792. VLC decreased from 77.4% to 77.1%. However, 7 countries experienced an increase ranging from 1.8% for Mozambique to 13.8% for Cameroon. VLS increased for all countries from 76.8% to 83.8%. This analysis shows variation in HIV VLC across 12 SSA countries. VLS consistently improved across all countries demonstrating resilience of countries during 2020. Countries should continue to improve clinical outcomes from C/ALHIV despite service disruptions that may occur during pandemic response. Competing Interests: The authors have declared that no competing interests exist. (Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.) |
| References: | Pediatr Res. 2021 Apr;89(5):1078-1086. (PMID: 32971527) Pediatr Infect Dis J. 2023 Apr 1;42(4):e102-e104. (PMID: 36728122) EClinicalMedicine. 2020 Jul 31;26:100483. (PMID: 33089116) J Int AIDS Soc. 2021 Jun;24(6):e25704. (PMID: 34105884) J Int AIDS Soc. 2021 Oct;24 Suppl 6:e25808. (PMID: 34713620) MMWR Morb Mortal Wkly Rep. 2022 Mar 25;71(12):447-452. (PMID: 35324881) MMWR Morb Mortal Wkly Rep. 2021 May 28;70(21):794-795. (PMID: 34043613) J Int AIDS Soc. 2020 Sep;23(9):e25622. (PMID: 32996705) BMC Public Health. 2021 Apr 10;21(1):704. (PMID: 33838676) J Int AIDS Soc. 2020 Aug;23(8):e25587. (PMID: 32767707) J Res Adolesc. 2021 Sep;31(3):531-545. (PMID: 34448296) Pediatr Infect Dis J. 2023 Feb 1;42(2):110-118. (PMID: 36638395) Clin Infect Dis. 2022 Aug 24;75(1):e1046-e1053. (PMID: 34791096) MMWR Morb Mortal Wkly Rep. 2021 May 28;70(21):775-778. (PMID: 34043612) AIDS Care. 2016;28(1):1-10. (PMID: 26278724) J Int AIDS Soc. 2017 Nov;20 Suppl 7:. (PMID: 29171190) Lancet Glob Health. 2020 Sep;8(9):e1132-e1141. (PMID: 32673577) AIDS Res Ther. 2021 Sep 19;18(1):62. (PMID: 34538268) Am J Trop Med Hyg. 2020 Sep;103(3):1191-1197. (PMID: 32705975) Br J Hosp Med (Lond). 2020 Aug 2;81(8):1-10. (PMID: 32845750) J Acquir Immune Defic Syndr. 2019 Jun 1;81(2):138-144. (PMID: 31095004) BMJ Open. 2020 Oct 5;10(10):e043763. (PMID: 33020109) PLoS One. 2021 Aug 27;16(8):e0256330. (PMID: 34449773) Respirology. 2021 Sep;26(9):893-894. (PMID: 34189800) Emerg Infect Dis. 2022 Oct;28(13):S59-S68. (PMID: 36502414) Curr HIV/AIDS Rep. 2022 Feb;19(1):46-53. (PMID: 35064888) |
| تواريخ الأحداث: | Date Created: 20240801 Latest Revision: 20240803 |
| رمز التحديث: | 20240803 |
| مُعرف محوري في PubMed: | PMC11293699 |
| DOI: | 10.1371/journal.pgph.0003513 |
| PMID: | 39088480 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!